Cat. No：GM-C26021
Product：IL-4/IL-13 Reporter 293 DDX35TM Cell Line
Cat. No：GM-C26021
Product：IL-4/IL-13 Reporter 293 DDX35TM Cell Line
Cell Growth Medium：DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
Interleukin-4 (IL-4) is a cytokine essential for differentiating Th0 cells into anti-inflammatory Th2 cells. Secreted mainly by Th2 cells, IL-4 promotes B cell proliferation and IgE antibody synthesis, crucial in allergies. IL-4 activates downstream signaling pathways through receptor binding.
Similarly, IL-13 is produced by T cells, including Th2 cells, and shares biological traits with IL-4. Its complex signaling involves receptors like IL-13Rα1, activating downstream pathways.
The IL-4/IL-13 Reporter 293 DDX35TM cell line is a clonal stable 293 cell line with signal-dependent expression of a luciferase reporter gene, and it endogenously expresses IL-4Rα and IL-13Rα1. When IL-4/IL-13 binds to the receptor, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can block this signal transmission. The measurement of luciferase activity indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of a neutralizing antibody targeting IL-4 and IL-13.
The IL-4/IL-13 Reporter 293 DDX35TM cell line was obtained through extensive monoclonal screening and multiple rounds of monoclonal selection. It possesses high stability, high sensitivity, and high amplification properties, meeting the standards for customers' batch library construction and release experiments.
Cat. No：GM-C26021
Product：IL-4/IL-13 Reporter 293 DDX35TM Cell Line
Cell Growth Medium：DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+0.75 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：DMEM+1% FBS+1% P.S
Interleukin-4 (IL-4) is a cytokine essential for differentiating Th0 cells into anti-inflammatory Th2 cells. Secreted mainly by Th2 cells, IL-4 promotes B cell proliferation and IgE antibody synthesis, crucial in allergies. IL-4 activates downstream signaling pathways through receptor binding.
Similarly, IL-13 is produced by T cells, including Th2 cells, and shares biological traits with IL-4. Its complex signaling involves receptors like IL-13Rα1, activating downstream pathways.
The IL-4/IL-13 Reporter 293 DDX35TM cell line is a clonal stable 293 cell line with signal-dependent expression of a luciferase reporter gene, and it endogenously expresses IL-4Rα and IL-13Rα1. When IL-4/IL-13 binds to the receptor, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can block this signal transmission. The measurement of luciferase activity indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of a neutralizing antibody targeting IL-4 and IL-13.
The IL-4/IL-13 Reporter 293 DDX35TM cell line was obtained through extensive monoclonal screening and multiple rounds of monoclonal selection. It possesses high stability, high sensitivity, and high amplification properties, meeting the standards for customers' batch library construction and release experiments.
